AI & Imaging
Response modeling enters AstraZeneca PSMA research
Nucs AI will adapt and validate image-based AI models for metastatic castration-resistant prostate cancer research involving PSMA-targeted radioconjugates.
Company
AstraZeneca
Company
Nucs AI will adapt and validate image-based AI models for metastatic castration-resistant prostate cancer research involving PSMA-targeted radioconjugates.